RJA
NARI

Raymond James & Associates’s Inari Medical, Inc. Common Stock NARI Stock Holding History

Raymond James & Associates’s Portfolio NARI Stock Details NARI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$609K Buy
14,771
+8,114
+122% +$390K ﹤0.01% 2996
2024
Q2 		$321K Buy
6,657
+96
+1% +$4.25K ﹤0.01% 3339
2024
Q1 		$315K Buy
6,561
+3,228
+97% +$172K ﹤0.01% 3350
2023
Q4 		$216K Buy
+3,333
New +$201K ﹤0.01% 3477
2023
Q1 		– Sell
-3,752
Closed -$238K – 4111
2022
Q4 		$238K Sell
3,752
-583
-13% -$42.3K ﹤0.01% 3347
2022
Q3 		$315K Sell
4,335
-83
-2% -$6.18K ﹤0.01% 3147
2022
Q2 		$300K Buy
4,418
+32
+0.7% +$2.3K ﹤0.01% 3238
2022
Q1 		$398K Buy
4,386
+76
+2% +$6.22K ﹤0.01% 3215
2021
Q4 		$393K Sell
4,310
-3,956
-48% -$339K ﹤0.01% 3268
2021
Q3 		$670K Sell
8,266
-10,056
-55% -$845K ﹤0.01% 2852
2021
Q2 		$1.71M Sell
18,322
-1,715
-9% -$166K ﹤0.01% 2212
2021
Q1 		$2.14M Buy
20,037
+11,587
+137% +$1.2M ﹤0.01% 1962
2020
Q4 		$738K Buy
+8,450
New +$597K ﹤0.01% 2539

Other funds holding NARI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HM
HCC Manager Chicago, Illinois $10.3M AUM 6.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Raymond James & Associates's NARI Position: Q3 2024 in Review

Raymond James & Associates increased its Inari Medical, Inc. Common Stock (NARI) stake by 122% in Q3 2024, buying an estimated $390K and bringing the position to 14,771 shares worth $609K. The position accounts for ﹤0.01% of the portfolio, ranked #2996.

Raymond James & Associates first reported a position in NARI in Q4 2020 and has held it in 13 quarters since. The position peaked at $2.14M in Q1 2021. 243 funds tracked by Wall St. Rank hold NARI as of Q3 2024.

  • Raymond James & Associates held 14,771 shares of Inari Medical, Inc. Common Stock worth $609K as of Q3 2024.
  • Raymond James & Associates bought 8,114 Inari Medical, Inc. Common Stock shares in Q3 2024, an estimated $390K.
  • Inari Medical, Inc. Common Stock made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #2996 holding.
  • Raymond James & Associates first reported a position in Inari Medical, Inc. Common Stock in Q4 2020 and has held it in 13 quarters since.
  • Raymond James & Associates's Inari Medical, Inc. Common Stock position peaked at $2.14M in Q1 2021.
  • 243 funds tracked by Wall St. Rank held Inari Medical, Inc. Common Stock as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.